Literature DB >> 27843000

Changes in gene expression induced by histamine, fexofenadine and osthole: Expression of histamine H1 receptor, COX-2, NF-κB, CCR1, chemokine CCL5/RANTES and interleukin-1β in PBMC allergic and non-allergic patients.

Natalia Karolina Kordulewska1, Elżbieta Kostyra2, Anna Cieślińska3, Michał Matysiewicz4, Ewa Fiedorowicz5, Edyta Sienkiewicz-Szłapka6.   

Abstract

INTRODUCTION: Fexofenadine (FXF) is a third-generation antihistamine drug and osthole is assumed as a natural antihistamine alternative. This paper compares results of histamine, FXF and osthole impact on HRH-1, COX-2, NF-κB-p50, CCR1 mRNA expression. We also measured mRNA expression of IL-1β and CCL5/RANTES in incubated peripheral blood mononuclear cells (PBMC) to compared how histamine, FXF and osthole had influence on expression level and interacts on product secretion.
OBJECTIVE: The purpose was to investigate expression pattern in asthma PBMC.
METHODS: The cultures were treated 72h with FXF and osthole. We measured mRNA expression of histamine HRH-1, COX-2, NF-κB-p50, CCR1, IL-1β and CCL5/RANTES with Real-Time PCR (RT-PCR).
RESULTS: The present study suggest that osthole may be a potential inhibitor of histamine H1 receptor activity. We also demonstrated that cells cultured with histamine increase COX-2 mRNA expression and osthole reduce it.
CONCLUSION: Allergy remains one of the most common chronic diseases in Europe and it is rapidly approaching epidemic proportions; with current predictions estimating that the number of allergy-afflicted will equal the healthy population by 2020. It is therefore paramount to find new pharmaceuticals which successfully combat allergic disease.
Copyright © 2016 Elsevier GmbH. All rights reserved.

Entities:  

Keywords:  Allergic disease; Antihistamine drugs; Cultures in vitro; Expression in PBMCs

Mesh:

Substances:

Year:  2016        PMID: 27843000     DOI: 10.1016/j.imbio.2016.11.004

Source DB:  PubMed          Journal:  Immunobiology        ISSN: 0171-2985            Impact factor:   3.144


  7 in total

1.  Expression of eosinophils, RANTES and IL-25 in the first phase of Hymenoptera venom immunotherapy.

Authors:  Krzysztof Pałgan; Magdalena Żbikowska-Götz; Zbigniew Bartuzi
Journal:  Postepy Dermatol Alergol       Date:  2019-04-01       Impact factor: 1.837

2.  Nasal DNA methylation differentiates severe from non-severe asthma in African-American children.

Authors:  Tao Zhu; Xue Zhang; Xiaoting Chen; Anthony P Brown; Matthew T Weirauch; Theresa W Guilbert; Gurjit K Khurana Hershey; Jocelyn M Biagini; Hong Ji
Journal:  Allergy       Date:  2020-11-25       Impact factor: 13.146

3.  Osthole Inhibits Expression of Genes Associated with Toll-like Receptor 2 Signaling Pathway in an Organotypic 3D Skin Model of Human Epidermis with Atopic Dermatitis.

Authors:  Natalia Karolina Kordulewska; Justyna Topa; Robert Stryiński; Beata Jarmołowska
Journal:  Cells       Date:  2021-12-28       Impact factor: 6.600

4.  Osthole Regulates Secretion of Pro-Inflammatory Cytokines and Expression of TLR2 and NF-κB in Normal Human Keratinocytes and Fibroblasts.

Authors:  Natalia Kordulewska; Justyna Topa; Anna Cieślińska; Beata Jarmołowska
Journal:  J Inflamm Res       Date:  2022-03-01

Review 5.  The role of human mast cells in allergy and asthma.

Authors:  Ghalya H Banafea; Sherin Bakhashab; Huda F Alshaibi; Peter Natesan Pushparaj; Mahmood Rasool
Journal:  Bioengineered       Date:  2022-03       Impact factor: 6.832

6.  C-C motif chemokine receptor 1 (CCR1) is a target of the EGF-AKT-mTOR-STAT3 signaling axis in breast cancer cells.

Authors:  Soon Young Shin; Da Hyun Lee; Jishin Lee; Chan Choi; Ji-Young Kim; Jeong-Seok Nam; Yoongho Lim; Young Han Lee
Journal:  Oncotarget       Date:  2017-10-10

7.  Effects of Osthole on Inflammatory Gene Expression and Cytokine Secretion in Histamine-Induced Inflammation in the Caco-2 Cell Line.

Authors:  Natalia K Kordulewska; Justyna Topa; Dominika Rozmus; Beata Jarmołowska
Journal:  Int J Mol Sci       Date:  2021-12-20       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.